FDA Says Medicis’ 510(k) Application to Market LIPOSONIX Does Not Provide Sufficient Data

July 7, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

July 6 (Reuters) - Medicis Pharmaceutical Corp (MRX.N) said health regulators indicated in a letter last week that data in its current filing for marketing approval of its body sculpting device, LipoSonix, was not sufficient.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

Food and Drug Administration (FDA)